These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383 [TBL] [Abstract][Full Text] [Related]
32. [Active immunotherapy in the treatment of haematological neoplasias]. Inogés S; Rodríguez Calvillo M; López Díaz de Cerio A; Zabalegui N; Melero I; Sánchez Ibarrola A; Rocha E; Bendandi M An Sist Sanit Navar; 2004; 27(1):45-62. PubMed ID: 15146205 [TBL] [Abstract][Full Text] [Related]
33. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777 [TBL] [Abstract][Full Text] [Related]
34. [Past, present and future of anti-idiotype vaccination]. Rodríguez Calvillo M; Inogés S; López Díaz de Cerio A; Zabalegui N; Panizo C; Hernández M; Pérez Calvo J; Prósper F; Melero I; Sánchez-Ibarrola A; Rocha E; Bendandi M Rev Med Univ Navarra; 2004; 48(3):14-23. PubMed ID: 15622921 [TBL] [Abstract][Full Text] [Related]
35. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma. Villanueva H; de Cerio AL; Inoges S; Pastor F; Soldevilla MM; Bendandi M Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168 [TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014 [TBL] [Abstract][Full Text] [Related]
38. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. Muraro E; Martorelli D; Dolcetti R Hum Vaccin Immunother; 2013 May; 9(5):1078-83. PubMed ID: 23406835 [TBL] [Abstract][Full Text] [Related]
39. Active idiotypic vaccination in a patient with biclonal follicular lymphoma. Barrios Y; Plaza A; Cabrera R; Yáñez R; Suárez E; Fernández MN; Díaz-Espada F Cancer Immunol Immunother; 2001 Apr; 50(2):87-92. PubMed ID: 11401030 [TBL] [Abstract][Full Text] [Related]
40. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Zabalegui N; Villanueva H; Bendandi M Crit Rev Oncol Hematol; 2004 Oct; 52(1):1-7. PubMed ID: 15363462 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]